Biologic therapy for early rheumatoid arthritis: The latest evidence

Current Opinion in Rheumatology

Volumn 20, Issue 3, 2008, Pages 314-319

  Castro Rueda, Hernan ^a   Kavanaugh, Arthur ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Biologic agents; Early rheumatoid arthritis; TNF inhibitors

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DEMYELINATING DISEASE; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOMODULATION; INFECTION; LUPUS LIKE SYNDROME; LYMPHOMA; MONOTHERAPY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41649095197     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282f5fcf6     Document Type: Review

References (31)

1. Bathon JM, Martin RW, Fleischmann RM. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586-1593.
2. Genovese MC, Bathon JM, Martin RW. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46:1443-1450. In this study, both methotrexate and TNF-α inhibitors are shown to have similar clinical outcomes when used as monotherapy, although radiographic outcomes are better with the latter. This was a pioneering study in the use of immunomodulatory agents (TNF-α inhibitors) for early RA. Later trials studied the effects of combination therapy (methotrexate and TNF-α blocking agents) in early RA.
3. St. Clair WE, van der Heijde DMFM, Smolen JS. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 2004; 50:3432-3443.
4. Smolen JS, van der Heijde DMFM, St. Clair W. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab. Results from the ASPIRE trial. Arthritis Rheum 2006; 54:702-710. Results from this study show that in patients with abnormal acute phase reactants and persistent disease activity, the combination of infliximab and MTX is superior to MTX monotherapy in terms of radiographic progression, supporting the use of intense goal-oriented combination therapy with a TNF-inhibitor and MTX in patients with early and clinically aggressive RA.
5. Breedveld F, Weisman M, Kavanaugh A. The PREMIER study. A multicenter randomized, double-blind trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26-37. This is another important trial which serves as proof of concept that in patients with early and aggressive RA, combination therapy with MTX and a TNF-α inhibitor is superior to either monotherapy in improving symptoms and controlling radiographic progression.
6. Genovese MC, Bathon JM, Fleischmann RM. Long-term safety, efficacy, and radiographic outcome with etanercept in patients with early rheumatoid arthritis. J Rheumatol 2005; 32:437-438.
7. Aletaha D, Funovits J, Keystone EC. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007; 56:3226-3235. In this study, the level of disease activity in early phases of treatment is a prognostic indicator of response to later therapy, supporting an early, tight therapeutic control of RA starting at early stages, in order to maintain better clinical control later on.
8. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthritis Rheum 2005; 52:3381-3390.
9. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF. Patient preferences for treatment: report from a randomized comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis 2007; 66:1227-1232.
10. Goekoop-Ruiteman YPM, de Vries-Bouwstra JK, Allaart CF. Comparison of strategies in early rheumatoid arthritis. A randomized trial. Ann Int Med 2007; 146:406-415.
11. Van der Bijl AE, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007; 56:2129-2134.
12. Chan KWA, Felson DT, Yood RA. The lag between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum 1994; 37:814-820.
13. Mottonen T, Hannonen P, Leirisalo-Repo M. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. FIN-RACo trial group. Lancet 1999; 354:952.
14. Boers M, Verhoeven AC, van der Linden S. Combination therapy in early rheumatoid arthritis: the COBRA study. Med Tijdschr Geneeskd 1997; 141:2428-2432.
15. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arth Rheum 2005; 52:3381-3390. BeSt is an important study which serves as evidence that early and aggressive therapy combining methotrexate with a TNF-α inhibitor has the benefit of less need for drug readjustments, with more potential for increasing drug-free remission.
16. Mitamura M, Nakamuto N, Yonekawa T. T cells are involved in the development of arthritis induced by antitype II collagen antibody. Int Immunopharmacol 2007; 10:1360-1368.
17. Tak PP, Smeets TJ, Daha MR. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997; 40:217-225.
18. Raza K, Falciani F, Curnow SJ. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005; 7:R784-R795.
19. Firestein GS. Pathogenesis of rheumatoid arthritis: how early is early? Arthritis Res Ther 2005; 7:R784-R795.
20. Van Dongen H, Van Aken J, Lard LR. Efficacy of methotrexate in patients with probable rheumatoid arthritis: A double-blind, randomized placebo-controlled trial. Arthritis Rheum 2007; 56:1424-1432. PROMPT provides evidence that a representative group of patients with early undifferentiated arthritis may not ever develop established RA and in fact may go into clinical remission without further differentiation. With this knowledge at hand, we understand that there is certainly a potential for overtreatment, and this needs to be taken into consideration.
21. Emery P, Breedveld F, Hall S. Remission rates in subjects with active early rheumatoid arthritis. 1 Year Results of the COMET Trial: combination of methotrexate and etanercept in active early rheumatoid arthritis. 71st Annual Scientific Meeting, American College of Rheumatology Concurrent Abstract Session. Late-breaking abstracts. No. L17. Boston, MA; 2007.
22. Durez P, Malghem J, Toukap AN. A randomized magnetic resonance imaging study comparing the effects of methotrexate alone in combination with infliximab, and methotrexate in combination with IV methylprednisolone. Arthritis Rheum 2007; 56:3919-3927. The authors of this study used MRI to determine early articular damage with different treatment modalities. This represents a step forward in the use of innovative imaging tools to evaluate radiographic outcomes in early RA.
23. Van Der Kooij SM, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK. Clinical and radiological efficacy of four different treatment strategies in patients with recent-onset rheumatoid arthritis: 4 year follow-up of the BeSt study. Arthritis Rheum 2007; 56 (Suppl 9):S299.
24. Van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YPM. Initial versus delayed treatment with infliximab plus methotrexate in patients with recent-onset rheumatoid arthritis. Results from the BeSt study. Arthritis Rheum 2007; 56 (Suppl 9):S147.
25. Curtis JR, Nivedita P, Xie A. Risk for serious bacterial infections among rheumatoid arthritis patients exposed to TNF-α antagonists. Arthritis Rheum 2007; 56:1125-1133.
26. Wallis RS, Broder MS, Wong JY. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-1265.
27. Bogartz T, Sutton AJ, Sweeting MJ. Anti TNF-alpha antibody therapy in rheumatoid arthritis and risk of serious infections and malignancies: a systematic review and meta-analysis of rare harmful effects in ranomized control trials. JAMA 2006; 295:2482.
28. Burmester GR, Mease PJ, Dijkmans BAC. Adalimumab clinical trial safety in multiple indications and reduction in mortality in rheumatoid arthritis. Arthritis Rheum 2006; 54 (Suppl 9):S232.
29. Kavanaugh A, Keystone EC. The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheum 2003; 21 (Suppl 31):S203-S208.
30. Smolen JS, van der Heijde DMFM, Emery P. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006; 54:716-722.
31. Van den Hout WB, Goekoop-Ruiterman YPM, Allaart CF. Cost-utility analysis of four treatment strategies for early rheumatoid arthritis: two year results of the BeSt study. EULAR, Annual European Congress of Rheumatology. Abstract: SAT0190. Amsterdam; 2006.